Haemopoietic stem cell transplantation in Australia and New Zealand, 1992–2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry

@article{NivisonSmith2005HaemopoieticSC,
  title={Haemopoietic stem cell transplantation in Australia and New Zealand, 1992–2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry},
  author={Ian Nivison-Smith and Kenneth Francis Bradstock and Anthony J. Dodds and Patricia A Hawkins and Jeffrey Szer},
  journal={Internal Medicine Journal},
  year={2005},
  volume={35}
}
Background:  Bone marrow and blood stem cell transplantation is now used as curative therapy for a range of haematological malignancies and other conditions. The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) has recorded transplant activity in Australia since 1992; transplant centres in New Zealand have corresponded with the Registry since 1998. 
Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998–2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group
Objective: To document haemopoietic stem cell transplantation (HSCT) activity and trends among paediatric patients in Australia and New Zealand.
Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004.
  • I. Nivison-Smith, K. Bradstock, J. Szer
  • Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2007
Late non‐relapse mortality among adult autologous stem cell transplant recipients: a nation‐wide analysis of 1482 patients transplanted in 1990–2003
TLDR
The incidence and causes of late (>100 d) non‐relapse mortality (NRM) in autologous stem cell transplant (ASCT) recipients is limited.
Consensus guidelines for ‘rainy day’ autologous stem cell harvests in New South Wales
Autologous stem cell transplantation (ASCT) has a well‐established role in the treatment of haematological malignancies. Stem cells are commonly collected following salvage chemotherapy although
A population-based cohort study of late mortality in adult autologous hematopoietic stem cell transplant recipients in Australia.
  • L. Ashton, Renate Le Marsney, C. Vajdic
  • Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2014
The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia.
TLDR
Although both types of stem cell transplantations are associated with a high short-term mortality and high cost, the cumulative gains in life-years of survivors can be substantial, resulting in ICERs compared with no transplantation that are usually considered acceptable, however there is less certainty about this conclusion with cord blood transplantation.
Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
  • J. Moore, I. Nivison-Smith, A. Dodds
  • Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2007
Early treatment‐related mortality in adult autologous stem cell transplant recipients: a nation‐wide survey of 1482 transplanted patients
TLDR
This nation‐wide survey indicated a low early TRM in ASCT recipients in general, but higher risks in patients with AL amyloidosis or NHL, in addition to patient selection, also optimization of transplant procedure may be needed in these patient groups to reduce earlyTRM.
Autologous stem cell transplantation beyond 60 years of age
TLDR
Progress in supportive care including amifostine and palifermin may increase feasibility of ASCT in elderly patients and further studies are needed in order to decrease toxicity of high-dose regimens in this patient group where co-morbid conditions may modify the toxicity of HDT in a clinically significant manner.
Stem cells--a clinical update.
  • B. Tuch
  • Medicine, Biology
    Australian family physician
  • 2006
TLDR
With the increasing public awareness of stem cell use, general practitioners need to be aware for which disorders these cells can, and are, being used.
...
...

References

SHOWING 1-10 OF 15 REFERENCES
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe
TLDR
An updated report on current practice of haemopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders in Europe is presented.
Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation.
TLDR
It is indicated that allogeneic BCT from matched and partially mismatched family donors result in faster engraftment than BMT without a significant increase in GVHD and there are indications of improved cost-effectiveness.
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
  • K. Branson, R. Chopra, S. Mackinnon
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
The low incidence of early GVHD enabled the subsequent administration of DLI to improve further clinical responses in this poor-risk group of lymphoma and myeloma patients and is a relatively safe option compared with conventional allogeneic transplantation for patients who have failed previous autologous SCT.
Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation.
TLDR
This retrospective comparison suggests that compared to marrow transplantation from HLA-identical donors, allogeneic PBSC transplants from Hla-Identical donors is associated with faster engraftment, fewer transfusions, and no greater incidence of acute or chronic GVHD.
Allogeneic peripheral blood stem cell transplantation for haematological malignancies – an analysis of kinetics of engraftment and GVHD risk
We have carried out an analysis of 44 patients undergoing allogeneic PBSC transplants from fully HLA-matched related donors with particular emphasis on engraftment kinetics and the incidence and
Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?
TLDR
The results of recent studies suggest that nonmyeloablative conditioning regimens may decrease the risks of bacterial infections associated with mucosal damage and persistent neutropenia; however, risks for late viral and fungal infections persist during severe graft versus host disease.
Clinical bone marrow and blood stem cell transplantation
  • J. Cahn
  • Medicine, Biology
    Leukemia
  • 2004
TLDR
The book is complete, extremely well presented and can be recommended to clinicians and scientists working in the field of hematopoietic stem cell transplantation.
Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
TLDR
The speed of neutrophil recovery seemed to be influenced strongly by using rhG-CSF post-transplant and marginally by the type of GVHD prophylaxis.
Recent advancements in the treatment of chronic myelogenous leukemia.
TLDR
Through rational drug development, STI571, a Bcr-Abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product targeted therapy, offering new hope for expanded treatment options for patients with CML.
Treatment of chronic myeloid leukaemia lessons and challenges
  • J. Goldman
  • Medicine, Biology
    International journal of hematology
  • 2002
TLDR
It is concluded that for the present allogeneic stem cell transplantation soon after diagnosis should continue to be offered as an option for selected patients and further experience with the use of imatinib as a single agent or in combination with other anti-leukemic agents may alter the picture in the near future.
...
...